Vonjo
Payments companies reported to CMS as associated with Vonjo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vonjo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vonjo
These are the largest totals companies reported as associated with Vonjo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jamie Koprivnikar | Hackensack, NJ | Medical Oncology | $263,898.31 |
| Karolina Faysman | Los Angeles, CA | Adult Health (Nurse Practitioner) | $187,608.15 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $182,583.35 |
| Jason Salganick | Phoenix, AZ | Medical Oncology | $174,917.95 |
| Mojtaba Akhtari | Omaha, NE | Hematology & Oncology | $172,442.51 |
| Raji Shameem | Orlando, FL | Medical Oncology | $172,131.56 |
| Daniel Landau | Orlando, FL | Hematology & Oncology | $155,401.49 |
| Mark Davis | Fort Worth, TX | Medical | $111,304.72 |
| Moshe Levy | Dallas, TX | Medical Oncology | $103,299.51 |
| Hana Safah | Baton Rouge, LA | Hematology & Oncology | $84,210.13 |
Prescribed Vonjo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.